ERCC5
Basic information
Region (hg38): 13:102845831-102875995
Previous symbols: [ "ERCM2", "XPGC" ]
Links
Phenotypes
GenCC
Source:
- xeroderma pigmentosum group G (Definitive), mode of inheritance: AR
- xeroderma pigmentosum group G (Strong), mode of inheritance: AR
- cerebrooculofacioskeletal syndrome 3 (Limited), mode of inheritance: AR
- xeroderma pigmentosum group G (Definitive), mode of inheritance: AR
- COFS syndrome (Supportive), mode of inheritance: AR
- xeroderma pigmentosum (Supportive), mode of inheritance: AR
- xeroderma pigmentosum-Cockayne syndrome complex (Supportive), mode of inheritance: AR
- cerebrooculofacioskeletal syndrome 3 (Strong), mode of inheritance: AR
- xeroderma pigmentosum group G (Strong), mode of inheritance: AR
- xeroderma pigmentosum group G (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Xeroderma pigmentosum, complementation group G; Xeroderma pigmentosum, complementation group G/Cockayne syndrome | AR | Dermatologic; Oncologic | Skin lesions can be treated (and possibly prevented in some cases) with a variety of methods, depending on the specific type of lesion; Sun/UV exposure (and other agents, such as tobacco smoke) should be avoided; Periodic surveillance for dermatologic manifestations can be beneficial | Craniofacial; Dermatologic; Musculoskeletal; Neurologic; Oncologic; Ophthalmologic | 492197; 11219864; 3620347; 8317483; 8818951; 9096355; 11228268; 11841555; 20301571; 24700531 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (6 variants)
- Xeroderma pigmentosum (5 variants)
- Xeroderma pigmentosum, group G (4 variants)
- Cerebrooculofacioskeletal syndrome 3 (2 variants)
- Xeroderma pigmentosum-Cockayne syndrome complex (1 variants)
- ERCC5-related disorder (1 variants)
- Xeroderma pigmentosum group G/Cockayne syndrome (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ERCC5 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 60 | 72 | ||||
missense | 124 | 13 | 149 | |||
nonsense | 8 | |||||
start loss | 0 | |||||
frameshift | 11 | 10 | 24 | |||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 1 | 6 | 3 | 1 | 11 | |
non coding | 12 | 24 | 38 | 74 | ||
Total | 14 | 21 | 148 | 97 | 51 |
Highest pathogenic variant AF is 0.0000394
Variants in ERCC5
This is a list of pathogenic ClinVar variants found in the ERCC5 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
13-102845848-A-G | Xeroderma pigmentosum, group G | Benign (Nov 11, 2018) | ||
13-102845887-C-T | Xeroderma pigmentosum, group G | Uncertain significance (Jan 12, 2018) | ||
13-102846025-T-C | Xeroderma pigmentosum, group G | Benign (Nov 11, 2018) | ||
13-102846026-G-C | Xeroderma pigmentosum, group G | Uncertain significance (Jan 13, 2018) | ||
13-102846067-G-C | Xeroderma pigmentosum, group G | Benign/Likely benign (Jun 01, 2023) | ||
13-102846075-A-C | Xeroderma pigmentosum, group G | Uncertain significance (Apr 27, 2017) | ||
13-102846111-C-A | Xeroderma pigmentosum, group G | Uncertain significance (Jan 12, 2018) | ||
13-102846121-A-G | Xeroderma pigmentosum, group G | Uncertain significance (Jan 12, 2018) | ||
13-102846141-A-G | Xeroderma pigmentosum, group G | Uncertain significance (Jan 13, 2018) | ||
13-102846193-G-A | Xeroderma pigmentosum, group G | Benign (Apr 03, 2019) | ||
13-102846195-C-T | Xeroderma pigmentosum, group G | Benign (Nov 11, 2018) | ||
13-102846266-C-G | not specified | not provided (Sep 19, 2013) | ||
13-102846266-C-T | not specified | not provided (Sep 19, 2013) | ||
13-102846272-G-A | Likely benign (Sep 01, 2023) | |||
13-102846277-A-C | Ovarian cancer | Likely pathogenic (Jan 01, 2022) | ||
13-102846298-A-C | Xeroderma pigmentosum, group G | Uncertain significance (Jan 15, 2018) | ||
13-102846314-G-A | Likely benign (Sep 01, 2022) | |||
13-102846322-C-T | not specified • Xeroderma pigmentosum, group G • Cerebrooculofacioskeletal syndrome 3 • Inborn genetic diseases | Conflicting classifications of pathogenicity (Aug 07, 2024) | ||
13-102846328-C-G | Uncertain significance (Nov 03, 2021) | |||
13-102846342-A-G | Xeroderma pigmentosum, group G • Hereditary cancer-predisposing syndrome • ERCC5-related disorder | Likely benign (Dec 21, 2020) | ||
13-102846344-C-G | Uncertain significance (Nov 03, 2021) | |||
13-102846349-C-A | Xeroderma pigmentosum, group G | Pathogenic (Mar 01, 2013) | ||
13-102846357-A-G | Likely pathogenic (Apr 15, 2023) | |||
13-102846367-C-CCGCCTTAAGTCCTAA | Likely benign (Jan 09, 2024) | |||
13-102846556-G-A | Likely benign (Jul 27, 2019) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ERCC5 | protein_coding | protein_coding | ENST00000355739 | 15 | 31152 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.73e-13 | 0.992 | 125698 | 0 | 50 | 125748 | 0.000199 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.118 | 628 | 636 | 0.987 | 0.0000359 | 7798 |
Missense in Polyphen | 220 | 225 | 0.97779 | 2766 | ||
Synonymous | -0.151 | 251 | 248 | 1.01 | 0.0000157 | 2258 |
Loss of Function | 2.64 | 28 | 47.7 | 0.587 | 0.00000243 | 580 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000301 | 0.000300 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000272 | 0.000272 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000168 | 0.000167 |
Middle Eastern | 0.000272 | 0.000272 |
South Asian | 0.000621 | 0.000621 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Single-stranded structure-specific DNA endonuclease involved in DNA excision repair. Makes the 3'incision in DNA nucleotide excision repair (NER). Acts as a cofactor for a DNA glycosylase that removes oxidized pyrimidines from DNA. May also be involved in transcription-coupled repair of this kind of damage, in transcription by RNA polymerase II, and perhaps in other processes too.;
- Disease
- DISEASE: Xeroderma pigmentosum complementation group G (XP-G) [MIM:278780]: An autosomal recessive pigmentary skin disorder characterized by solar hypersensitivity of the skin, high predisposition for developing cancers on areas exposed to sunlight and, in some cases, neurological abnormalities. The skin develops marked freckling and other pigmentation abnormalities. Some XP-G patients present features of Cockayne syndrome, cachectic dwarfism, pigmentary retinopathy, ataxia, decreased nerve conduction velocities. The phenotype combining xeroderma pigmentosum and Cockayne syndrome traits is referred to as XP-CS complex. {ECO:0000269|PubMed:10447254, ECO:0000269|PubMed:11228268, ECO:0000269|PubMed:11841555, ECO:0000269|PubMed:12060391, ECO:0000269|PubMed:23255472, ECO:0000269|PubMed:7951246, ECO:0000269|PubMed:9096355}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cerebro-oculo-facio-skeletal syndrome 3 (COFS3) [MIM:616570]: A disorder of prenatal onset characterized by microcephaly, congenital cataracts, facial dysmorphism, neurogenic arthrogryposis, growth failure and severe psychomotor retardation. COFS is considered to be part of the nucleotide-excision repair disorders spectrum that include also xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome. {ECO:0000269|PubMed:24700531}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Nucleotide excision repair - Homo sapiens (human);Nucleotide Excision Repair ;DNA Repair;Formation of Incision Complex in GG-NER;Dual Incision in GG-NER;Global Genome Nucleotide Excision Repair (GG-NER);Dual incision in TC-NER;Transcription-Coupled Nucleotide Excision Repair (TC-NER);Nucleotide Excision Repair
(Consensus)
Recessive Scores
- pRec
- 0.493
Intolerance Scores
- loftool
- 0.898
- rvis_EVS
- 0.55
- rvis_percentile_EVS
- 81.13
Haploinsufficiency Scores
- pHI
- 0.0814
- hipred
- Y
- hipred_score
- 0.572
- ghis
- 0.551
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.843
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ercc5
- Phenotype
- digestive/alimentary phenotype; immune system phenotype; liver/biliary system phenotype; hematopoietic system phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- transcription-coupled nucleotide-excision repair;nucleotide-excision repair;nucleotide-excision repair, preincision complex stabilization;nucleotide-excision repair, preincision complex assembly;nucleotide-excision repair, DNA incision, 3'-to lesion;nucleotide-excision repair, DNA incision, 5'-to lesion;response to UV;UV protection;response to UV-C;nucleotide-excision repair, DNA incision;negative regulation of apoptotic process
- Cellular component
- nucleotide-excision repair complex;nucleus;nucleoplasm;DNA replication factor A complex
- Molecular function
- bubble DNA binding;RNA polymerase II complex binding;double-stranded DNA binding;single-stranded DNA binding;endodeoxyribonuclease activity;protein binding;protein homodimerization activity;protein-containing complex binding;metal ion binding;protein N-terminus binding